There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biolase (BIOL – Research Report), Supernus Pharmaceuticals (SUPN – Research Report) and Intra-Cellular Therapies (ITCI – Research Report) with bullish sentiments.
Biolase (BIOL)
Colliers Securities analyst Kyle Bauser reiterated a Buy rating on Biolase today and set a price target of $2.00. The company’s shares closed last Monday at $0.34, close to its 52-week low of $0.31.
According to TipRanks.com, Bauser ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biolase with a $2.00 average price target, representing a 506.1% upside. In a report issued on January 10, Maxim Group also reiterated a Buy rating on the stock with a $2.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Supernus Pharmaceuticals (SUPN)
Jefferies analyst David Steinberg maintained a Buy rating on Supernus Pharmaceuticals today and set a price target of $44.00. The company’s shares closed last Monday at $29.14.
According to TipRanks.com, Steinberg is a 4-star analyst with an average return of
Supernus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $40.50.
Intra-Cellular Therapies (ITCI)
In a report issued on January 21, Andrew Tsai from Jefferies maintained a Buy rating on Intra-Cellular Therapies, with a price target of $85.00. The company’s shares closed last Monday at $44.34.
According to TipRanks.com, Tsai is a 1-star analyst with an average return of
Currently, the analyst consensus on Intra-Cellular Therapies is a Strong Buy with an average price target of $62.71, a 48.6% upside from current levels. In a report issued on January 6, RBC Capital also maintained a Buy rating on the stock with a $55.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIOL:
- Barrington Thinks Chegg’s Stock is Going to Recover
- Barrington Remains a Buy on Grand Canyon Education (LOPE)
- Columbus Mckinnon (CMCO) Receives a Buy from Barrington
- Calix (CALX) Receives a Buy from Barrington
- Analysts Are Bullish on Top Services Stocks: Adtalem Global Education (ATGE), Sharps Compliance (SMED)
